Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS. Shaked Y, et al. Among authors: roodhart jm. Cancer Cell. 2008 Sep 9;14(3):263-73. doi: 10.1016/j.ccr.2008.08.001. Cancer Cell. 2008. PMID: 18772115 Free PMC article.
Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF.
Langenberg MH, Nijkamp MW, Roodhart JM, Snoeren N, Tang T, Shaked Y, van Hillegersberg R, Witteveen PO, Vermaat JS, Kranenburg O, Kerbel RS, Medema RH, Borel Rinkes IH, Voest EE. Langenberg MH, et al. Among authors: roodhart jm. Cancer Biol Ther. 2010 May 1;9(9):743-8. doi: 10.4161/cbt.9.9.11551. Epub 2010 May 18. Cancer Biol Ther. 2010. PMID: 20215863
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, Voest EE. Langenberg MH, et al. Among authors: roodhart jm. Clin Cancer Res. 2010 Apr 1;16(7):2187-97. doi: 10.1158/1078-0432.CCR-09-2436. Epub 2010 Mar 16. Clin Cancer Res. 2010. PMID: 20233884 Clinical Trial.
Vascular disrupting agents (VDAs) in anticancer therapy.
Daenen LG, Roodhart JM, Shaked Y, Voest EE. Daenen LG, et al. Among authors: roodhart jm. Curr Clin Pharmacol. 2010 Aug;5(3):178-85. doi: 10.2174/157488410791498815. Curr Clin Pharmacol. 2010. PMID: 20406172 Review.
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Langenberg MHG, Witteveen PO, Roodhart J, Lolkema MP, Verheul HMW, Mergui-Roelvink M, Brendel E, Krätzschmar J, Loembé B, Nol-Boekel A, Christensen O, Schellens JHM, Voest EE. Langenberg MHG, et al. Ann Oncol. 2011 Nov;22(11):2508-2515. doi: 10.1093/annonc/mdq767. Epub 2011 Mar 4. Ann Oncol. 2011. PMID: 21378200 Free article. Clinical Trial.
64 results